These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9157096)

  • 1. A preliminary analysis of interactive effects between common classroom contingencies and methylphenidate.
    Northup J; Jones K; Broussard C; DiGiovanni G; Herring M; Fusilier I; Hanchey A
    J Appl Behav Anal; 1997; 30(1):121-5. PubMed ID: 9157096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid method for evaluating the necessity for both a behavioral intervention and methylphenidate.
    Kayser KH; Wacker DP; Derby KM; Andelman MS; Golonka Z; Stoner EA
    J Appl Behav Anal; 1997; 30(1):177-80. PubMed ID: 9157098
    [No Abstract]   [Full Text] [Related]  

  • 3. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.
    Pelham WE; Burrows-Maclean L; Gnagy EM; Fabiano GA; Coles EK; Tresco KE; Chacko A; Wymbs BT; Wienke AL; Walker KS; Hoffman MT
    Exp Clin Psychopharmacol; 2005 May; 13(2):111-26. PubMed ID: 15943544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further analysis of the separate and interactive effects of methylphenidate and common classroom contingencies.
    Northup J; Fusilier I; Swanson V; Huete J; Bruce T; Freeland J; Gulley V; Edwards S
    J Appl Behav Anal; 1999; 32(1):35-50. PubMed ID: 10201102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential evaluation of behavioral treatments and methylphenidate dosage for children with attention deficit hyperactivity disorder.
    Gulley V; Northup J; Hupp S; Spera S; LeVelle J; Ridgway A
    J Appl Behav Anal; 2003; 36(3):375-8. PubMed ID: 14596580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of methylphenidate on a functional analysis of disruptive behavior: a replication and extension.
    Dicesare A; McAdam DB; Toner A; Varrell J
    J Appl Behav Anal; 2005; 38(1):125-8. PubMed ID: 15898483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention deficit hyperactivity disorder in children.
    Ramchandani P; Joughin C; Zwi M
    Clin Evid; 2002 Dec; (8):280-90. PubMed ID: 12603883
    [No Abstract]   [Full Text] [Related]  

  • 8. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings.
    Gadow KD; Nolan EE; Sverd J; Sprafkin J; Paolicelli L
    J Am Acad Child Adolesc Psychiatry; 1990 Sep; 29(5):710-8. PubMed ID: 2228923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate.
    Swanson JM; Wigal SB; Udrea D; Lerner M; Agler D; Flynn D; Fineberg E; Davies M; Kardatzke D; Ram A; Gupta S
    Psychopharmacol Bull; 1998; 34(4):825-32. PubMed ID: 10513459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial treatments for attention-deficit/hyperactivity disorder in children.
    Barkley RA
    J Clin Psychiatry; 2002; 63 Suppl 12():36-43. PubMed ID: 12562060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?
    Killeen MR
    J Child Fam Nurs; 2000; 3(1):46-8. PubMed ID: 11022478
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peer-mediated reinforcement plus prompting as treatment for off-task behavior in children with attention deficit hyperactivity disorder.
    Flood WA; Wilder DA; Flood AL; Masuda A
    J Appl Behav Anal; 2002; 35(2):199-204. PubMed ID: 12102141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
    Olders H
    J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
    [No Abstract]   [Full Text] [Related]  

  • 16. Methylphenidate-associated enuresis in attention deficit hyperactivity disorder.
    Ghanizadeh A
    J Pediatr Urol; 2008 Aug; 4(4):306-7. PubMed ID: 18644535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 19. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.